news
Novel compound for targeted alpha therapy
NpG-D-PSMA has shown great potential for targeted alpha therapy to combat prostate cancer.
List view / Grid view
Drug Development
news
Elucidating the aggregation rules for short peptides
The findings could aid the design of more stable drugs and improve the understanding of diseases linked to peptide aggregation.
news
New DNA aptamer stabilises atherosclerosis plaques
The nucleic acid drug, iSN04, could have applications for pathological angiogenesis involved in atherosclerosis, cancer, and retinopathy.
article
Women in STEM with Nadine Sprangers
Nadine Sprangers is Vice President, Head of Global Oncology Value, Access and Pricing at Daiichi Sankyo. Holding a PharmD degree and two Master’s Degrees, she leads a team of 50 people responsible for setting the global strategic framework for Pricing, Reimbursement, and Access (PRA), Health Economics and Outcome Research (HEOR),…
podcasts
Combatting disease with antibody drug conjugates
Tune into this episode where we investigate how antibody drug conjugates can be optimised, as well as the future of the field.
article
Part two: the impact of poor data quality
In this four-part series, Dr Raminderpal Singh will discuss the challenges surrounding limited data quality, and some pragmatic solutions. In this second article, he discusses the problems that occur when using data of poor quality.
article
Patient-centred oncology: transforming drug development
As deeper understanding of disease makes the development and commercialisation of oncology drugs more complex, developers are under more pressure than ever to deliver value-based treatments. In this article, Rebecca Goldstein, Senior Principal, Strategic Consulting at Envision Pharma Group, explores anchoring a programme to patient experience as a solution.
article
Women in STEM with Charlotte Owens
As Senior Vice President and Head of Global Medical Affairs & Outcomes Research at the global healthcare company Organon, Charlotte Owen’s extensive work is advancing women’s healthcare and overcoming health inequities.
news
New two-step vaccination strategy for influenza
The novel strategy demonstrates a strong immune response, both body-wide and specifically in the upper respiratory tract, in porcine models.
article
The art and science of drug formulation
Drug formulation is a cornerstone of modern medicine, turning raw active ingredients into consumable, effective therapies. This critical phase in drug development ensures that medications are safe, effective, and user-friendly. Here Ningfeng Fiona Li, founder and CEO of VasoDynamics, explores the world of drug formulation from its foundations to exploring…
news
Type 1 regulatory cells limit immunotherapy success
Scientists discovered the number of Tr1 cells increased as tumours grew larger, making mice insensitive to immunotherapy.
article
Out of the lab and into patients: targeting APE1/Ref-1
We had the privilege of speaking to Dr Mark R. Kelley, Associate Director of Basic Science at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, and Betty and Earl Herr Professor in Pediatric Oncology Research, prior to his talk at PharmSci 360 in 2024. He elucidates what makes…
article
Shaping drug development success: how does artwork play a role?
Proactive approaches to labelling and artwork in preclinical stages of drug development reduce delays, minimise risk and expedite time to market.
podcasts
Advanced techniques in toxicity testing
Tune in to this episode where we explore how innovative assays and human-relevant cell models are transforming toxicity screening in drug development.
news
Spinal muscular atrophy: searching for a cure
Organoids with SMA-pathology uncovered key findings about the disease, which could be utilised to develop new therapeutic options.
